Skip header and navigation

2 records – page 1 of 1.

Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV.

https://arctichealth.org/en/permalink/ahliterature204544
Source
Acta Oncol. 1998;37(4):375-8
Publication Type
Article
Date
1998
Author
M. Nilbert
G. Saeter
I. Elomaa
O R Monge
T. Wiebe
T A Alvegård
Author Affiliation
Department of Oncology, University Hospital, Lund, Sweden.
Source
Acta Oncol. 1998;37(4):375-8
Date
1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bleomycin - administration & dosage
Bone Neoplasms - pathology - radiotherapy - surgery - therapy
Child
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Dactinomycin - administration & dosage
Doxorubicin - administration & dosage
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Male
Methotrexate - administration & dosage
Neoplasm Recurrence, Local
Orthopedic Procedures
Radiotherapy, Adjuvant
Sarcoma, Ewing - pathology - radiotherapy - surgery - therapy
Scandinavia
Survival Analysis
Treatment Outcome
Vincristine - administration & dosage
Abstract
A report on the long-term follow up of the first cooperative Scandinavian Sarcoma Group study in Ewing's sarcoma of bone is presented. Fifty-two previously untreated patients entered the study between 1984 and 1990. Half of the tumors were located in the extremities and one quarter in the pelvis. The combined modality treatment consisted of 5 cycles of chemotherapy--including vincristine, methotrexate, doxorubicin, cyclophosphamide, bleomycin and dactinomycin. The first two cycles were followed by local resection or amputation in 35 patients and by radiotherapy alone in 17 patients. When surgery was not performed, was incomplete or yielded poor margins radiotherapy was given at a dose of 40-60 Gy. Local tumor relapses developed in 10 patients and in all but one patient were accompanied by metastatic disease. Five patients had metastasis at diagnosis and distant metastases developed after primary treatment in 27 patients after a median of 14 months. The median follow-up time for the 20 surviving patients is 10 years. At 5 years the tumor-related survival was 46% and the metastasis-free survival 43%. Late tumor relapses occurred in 4 patients, which reduced the 10-year tumor related survival to 41% and the metastasis-free survival to 38%. Histopathological tumour response correlated with survival with 5-year metastasis-free survival rates of 73% for the good responders and 35% for the poor responders.
PubMed ID
9743460 View in PubMed
Less detail